

ATTACHMENT 1

PLAINTIFF'S EXHIBIT LIST – ATTACHMENT #1

#	Description	Bates Number	Pre-Admit?
1	Photographs of Decedent, family, and friends.		No
2	State of Louisiana, Certification of Death, certified on 06/27/2023.	MOLLER_000001	No
3	Coroner's Autopsy Report/Medical Examiner (Defatta) of St. Tammany Parish Coroner's Office Postmortem Forensic Medical Examination Report, including NMS Labs Toxicology Report issued 02/24/2023	MOLLER000007-000016	No
4	St. Tammany Parish Coroner's Office file	TAMMANYCORONER_MOLLER00001-00040	Yes
5	St. Tammany Parish Fire Department District #4 Patient Care Record	ST. TAMMANYFD_MOLLER0001-00118	Yes
6	NMS Litigation Support Package: 23055002		Yes
7	Jesse E. Edwards Registry of Cardiovascular Disease heart autopsy report	MOLLER_00003-000006	Yes
8	Fact of Death Letter signed by Carles Preston, M.D., Coroner for the Parish of St. Tammany	MOLLER_000002	No
9	Photos of the kratom packages discovered in Decedent's room	MOLLER_000023-000026	No
10	Funeral Expenses	MOLLER_000017-000022; Moller_000027-000028 (urn)	No
11	FDA Import Alert 54-15		No
12	FDA Import Alert 66-41		No
13	FDA Import Alert 99-45		No

#	Description	Bates Number	Pre-Admit?
14	Case 2:24-cv-00228-WBV-DPC Document 196 Filed 12/18/25 Page 1-14		No
15	FDA letter to American Botanicals Corporation, dated Nov. 5, 2021		No
16	FDA letter to BD Botanicals Ltd., dated October 25, 2019		No
17	FDA letter to INI Botanicals, dated Dec. 20, 2016		No
18	FDA letter to Mr. Luke Dodd, dated Sep. 22, 2015		No
19	FDA Warning Letters: Warning letter to Amafruits, LLC, dated July 21, 2017		No
20	Warning letter to For Earth, Inc., dated Aug. 19, 2011		No
21	Warning letter to Tennessee Scientific, Inc./Scientific Formulations LLC, dated Feb. 1, 2011		No
22	Warning letter to ZEO Health Ltd., dated Jun. 29, 2007		No
23	Warning letter to USApeptide.com, dated February 26, 2025		No
24	Warning letter to Umbrella, dated May 18, 2021		No
25	Warning letter to Top Health Manufacturing, LLC, dated June 3, 2024		No
26	Warning letter to Sunshine Trading Company, Inc. d/b/a Nova Tea and Nova Kratom, dated July 3, 2023		No
27	Warning letter to Omni Consumer Products, LLC d/b/a YoKratom, dated June 30, 2022		No

#	Description	Bates Number	Pre-Admit?
28	Warning letter to Market America, Inc., dated February 12, 2020		No
29	Warning letter to KratomNC, dated May 16, 2019		No
30	Warning letter to Kratom Exchange, dated June 30, 2022		No
31	Warning letter to Klarity Kratom, dated June 30, 2022		No
32	Warning letter to Herbsens Botanicals, dated June 30, 2022		No
33	Warning letter to Cali Botanicals, LLC, dated June 11, 2019		No
34	Warning letter to BHP Holdings, Inc., d/b/a BioPure Healing Products, dated June 17, 2020		No
35	Warning letter to Xcel Research, LLC, dated December 10, 2024		No
36	Warning letter to Formulife, Inc., Purus Labs, Inc. d/b/a Dark Cyde Supplements, dated January 18, 2012		No
37	Warning letter to Big Easy Confections, LLC, dated August 14, 2014		No
38	FDA and Kratom webpage accessible at: https://www.fda.gov/news-events/public-health-focus/fda-and-kratom (last accessed December 15, 2025)		No
39	New Dietary Ingredient Notification (NDIN) 1264 for NPI-001, A Dried Kratom Leaf Powder, dated October 21, 2022, rejected by FDA.		No
40	Drug Enforcement Agency Kratom Fact Sheet, published April 2020.		No

#	Description	Bates Number	Pre-Admit?
41	FDA statement of Scott Gotlieb, MD, dated September 11, 2018.		No
42	FDA News Release, FDA warns companies selling illegal, unapproved kratom marketed for opioid cessation, pain treatment and other medical uses, dated May 22, 2018.		No
43	FDA News Release, FDA Announces Seizures of Adulterated Dietary Supplements Containing Kratom, dated May 21, 2021.		No
44	FDA response letter to NDIN 1264 for NPI-001 dated January 4, 2023 from Phillip Yeager.		No
45	CAERS Database (Center for Food Safety and Applied Nutrition's Adverse Event Reporting System) reports for OPMS Kratom.		No
46	Excerpts of the OPMkratom.com website, including warnings and disclaimers.		No
47	Excerpts of the OPMSkratom.com website, including warnings and disclaimers. See e.g.	DEF_MOLLER_007245-007249	Yes
48	August 2, 2024, E-mail from Seth Heller to Gwendolyn Payton and Benjamin England.		No
49	U.S. Dept. of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research, Assessment of Abuse Potential of Drugs – Guidance for Industry, January 2017.		No
50	Report to Jonathan Emord, ESQ. from Robert Verkerk, MSc, DIC, PhD, FACN, Dated October 7, 2024	(Pinney_00006308-0006337)	No
51	NP Biotech, LLC, Kratom Formulations, Pre-CTA Consultation Meeting Minutes	(Pinney_00088357-00088363)	No

#	Description	Bates Number	Pre-Admit?
52	NP Biotech, LLC Investigators Brochure	DEF_MOLLER_003799-004043	No
53	IRB documents related to NP Biotech, LLC & Nutrasource human clinical study	DEF_MOLLER_004044-004225	No
54	FDA, Pilot, Dose-Finding Study of Kratom Alkaloids: Study Design Updates, February 15, 2024	DEF_MOLLER_004226-004269	No
55	Martian Sales: Specification Sheet	DEF_MOLLER_004701-004707	No
56	Certificates of Analysis for OPMS kratom: DEF_MOLLER_007305-06	DEF_MOLLER_007305-06	No
56 (a)		DEF_MOLLER_007307-08	No
56 (b)		DEF_MOLLER_007309-10	No
56 (c)		DEF_MOLLER_007311-12	No
56 (d)		DEF_MOLLER_007313-14	No
56 (e)		DEF_MOLLER_004270	No
56 (f)		DEF_MOLLER_004701-004707	No
56 (g)		DEF_MOLLER_007462-007465	No
56 (h)		DEF_MOLLER_007466-007469	No
56 (i)		DEF_MOLLER_007470-007473	No

#	Description	Bates Number	Pre-Admit?
56 (j)		DEF_MOLLER_007474-007477	No
56 (k)		DEF_MOLLER_007478-007481	No
57	Louisiana Organ Procurement Agency File	LOPA000001-000093	Yes
58	Aggarwal, Geeta, et al., <i>Death from Kratom toxicity and the possible role of intralipid</i> , Journal of the Intensive Care Society, Vol. 19(1) 61-63 (2018)		No
59	Chang Chien, George C., DO, et al., <i>Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential</i> , Pain Physician Journal, 20:E195-E198 (2017)		No
60	Giroir, Brett. P., MD et al., August 16, 2018, comment on October 17, 2017, letter "Basis for the recommendations to control mitragynine and 7-hydroxymitragynine in Schedule 1 of the Controlled Substances Act."		No
61	Henningfield, Jack E., et al., <i>The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research</i> , Psychopharmacology, 235:573-589 (2018).		No
62	Henningfield, Jack E., et al., <i>Risk of death associated with kratom use compared to opioids</i> , Preventive Medicine, 128:105851 (2019).		No
63	Hill, Rob, et al., <i>The respiratory depressant effects of mitragynine are limited by its conversion to 7-OH mitragynine</i> , Br. J. Pharmacol., 179:3875-3885 (2022).		No

#	Description	Bates Number	Pre-Admit?
64	Papsun, Donna M., <i>The Trouble with Kratom: Analytical and Interpretative Issues Involving Mitragynine</i> , Journal of Analytical Toxicology, 1-15 (2019).		No
65	Wilson, Lisa L., et al., <i>Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence</i> , Drug and Alcohol Dependence, Vol. 216, 108310 (2020).		No
66	Kamble, Shyam H., et al., <i>Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids</i> , Toxicology Letters, 319, 148-154 (2019).		No
67	Kamble, Shyam H., et al., <i>Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy</i> , ACS Pharmacol. Transl. Sci., 6:1063-1068 (2020).		No
68	Muller, Elisabeth, et al., <i>Kratom instrumentalization for severe pain self-treatment resulting in addition – A case report of acute and chronic subjective effects</i> , Heliyon (2020).		No
69	Singh, Darsahn, et al., <i>Current and Future Potential Impact of COVID-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use</i> , Frontiers in Psychiatry, Vol. 11, Art. 574483 (2020)		No
70	Mohammad Farris Iman Leong Bin Abdullah and Darshan Singh, <i>Assessment of Cardiovascular Functioning Among Regular Kratom (Mitragyna speciosa Korth) Users: A Case Series</i> , Frontiers in Pharmacology, Vol. 12, Art. 723567 (2021).		No
71	Mohammad Farris Iman Leong Bin Abdullah and Darshan Singh, <i>The Adverse</i>		No

#	Description	Bates Number	Pre-Admit?
	<i>Cardiovascular Effects and Cardiotoxicity of Kratom (Mitragyna speciosa Korth.): A Comprehensive Review</i> , Frontiers in Pharmacology, Vol. 12, Art. 726003 (2021).		
72	Damodaran, Thenmoly, et al., <i>Comparative Toxicity Assessment of Kratom Decoction, Mitragynine and Speciociliatine Versus Morphine on Zebrafish (Danio rerio) Embryos</i> , Frontiers in Pharmacology, Vol. 12, Art. 714918 (2021)		No
73	Henningfield, Jack E., et al., <i>Kratom Abuse Potential 2021: An Updated Eight Factor Analysis</i> , Frontiers in Pharmacology, Vol. 12, Art. 775073 (2022)		No
74	McCurdy, Christopher R., <i>Kratom: What science is discovery about the risks and benefits of a controversial herb</i> , The Conversation, Jan. 22, 2021.		No
75	Prevete, Elisabeth, et al., <i>A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans</i> , Hum Psychopharmacol Clin Exp., e2805 (2021).		No
76	Buckhalter, Shoshana, <i>The Antidepressant-Like and Analgesic Effects of Kratom Alkaloids are accompanied by Changes in Low Frequency Oscillations but not ΔFosB Accumulation</i> , Frontiers in Pharmacology, Vol. 12, Art. 696461 (2021).		No
77	Henningfield, Jack E., et al., <i>Respiratory effects of oral mitragynine and oxycodone in a rodent model</i> , Psychopharmacology, 239:3793-3804 (2022).		No
78	Stanciu, Cornel, et al., <i>Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature</i> , The		No

#	Description	Bates Number	Pre-Admit?
	American Journal of Drug and Alcohol Abuse (2022).		
79	Swogger, Marc T., et al., <i>Understanding Kratom Use: A Guide for Healthcare Providers</i> , Frontiers in Pharmacology, Vol. 13, Art. 801855 (2022).		No
80	World Health Organization, <i>Pre-Review Report: Kratom (Mytragyna speciosa), mitragynine, and 7-hydroxymitragynine</i> , Expert Committee on Drug Dependence, Forty-fourth Meeting, Geneva, 11-15 October 2021.		No
81	Ou, Oliver, et al., <i>Kratom Related Adverse Event Reports from the FDA CFSAN Adverse Event Reporting System (CAERS)</i> , 2021		No
82	Turla, Toby, et al., <i>Reported association between kratom and seizures: a systemic review</i> , Frontiers in Pharmacology, 16:1623835 (2025)		No
83	Rosenthal, Robert, et al., <i>Benign or Malignant Anomaly? Very High Takeoff of the Left Main Coronary Artery above the Left Coronary Sinus</i> , Tex. Heart Inst. J 2012;39(4)538-41.		No
84	Hanapi, Nur Aziah, et al., <i>Kratom Alkaloids: Interactions With Enzymes, Receptors, and Cellular Barriers</i> , Frontiers in Pharmacology, 12:751656 (2021)		No
85	Krantz, Mori, et. al., <i>Ventricular Arrhythmias Associated With Over-the-Counter and Recreational Opioids</i> , Journal of the American College of Cardiology, Vol. 81, No. 23, (2023).		No
86	Li, Xiaotong, et al., <i>An evaluation of adverse drug reactions and outcomes</i>		No

#	Description	Bates Number	Pre-Admit?
	<i>attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021, Cln. Transl. Sci.</i> 2023;00:1-10.		
87	Huestis, Marilyn, et al., <i>Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder</i> , <i>Molecules</i> 2024, 29(5), 984.		No
88	Eckhardt, Lee, Nickel, Andrew. <i>The Changing Complexities of Opioid-Related Sudden Death</i> . <i>J Am Coll Cardiol</i> 2023;81:2269–2271		No
89	Miller et. al. <i>Kratom Cardiotoxicity: Reversible Brugada Pattern and QTc Prolongation</i> . <i>J Am Coll CardiolCase Rep</i> . 2025;30:103109		No
90	Jain et. al. <i>A Kratomic Bomb. Cardiotoxicities From Mitragyna speciosa Extract</i> . <i>J Am Coll CardiolCase Rep</i> . 2025;30:103110		No
91	Takayama, H. <i>Chemistry and Pharmacology of Analgesic Indole Alkaloids from the Rubiaceous Plant, Mitragyna Speciosa</i> . <i>Chem. Pharm. Bull. (Tokyo)</i> 2004, 52 (8), 916–928. https://doi.org/10.1248/cpb.52.916 .		No
92	Zuarth Gonzalez, J. D.; Ragsdale, A. K.; Mukhopadhyay, S.; McCurdy, C. R.; McMahon, L. R.; Obeng, S.; Wilkerson, J. L. <i>Mitragynine and 7-Hydroxymitragynine: Bidirectional Effects on Breathing in Rats</i> . <i>J. Pharmacol. Exp. Ther.</i> 2025, 392 (11), 103720. https://doi.org/10.1016/j.jpet.2025.103720 .		No

#	Description	Bates Number	Pre-Admit?
93	Lu, J.; Wei, H.; Wu, J.; Jamil, M. F. A.; Tan, M. L.; Adenan, M. I.; Wong, P.; Shim, W. <i>Evaluation of the Cardiotoxicity of Mitragynine and Its Analogues Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes</i> . PLoS ONE 2014, 9 (12), e115648. https://doi.org/10.1371/journal.pone.0115648		No
94	Abdullah, H. M. A.; Haq, I.; Lamfers, R. <i>Cardiac Arrest in a Young Healthy Male Patient Secondary to Kratom Ingestion: Is This 'legal High' Substance More Dangerous than Initially Thought ?</i> BMJ Case Rep. 2019, 12 (7), e229778. https://doi.org/10.1136/bcr-2019-229778 .		No
95	Schulz, M.; Schmoldt, A.; Andresen-Streichert, H.; Iwersen-Bergmann, S. <i>Revisited: Therapeutic and Toxic Blood Concentrations of More than 1100 Drugs and Other Xenobiotics</i> . Crit. Care 2020, 24 (1), 195. https://doi.org/10.1186/s13054-020-02915-5 .		No
96	O'Malley Olsen, Emily, et al., Center for Disease Control and Prevention, <i>Notes from the Field: Unintentional Drug Overdose Deaths with Kratom Detected</i> , April 12, 2019		No
97	Johnson Foods, LLC 2022 Form 1120-S	JF000514-000539	No
98	Johnson Foods, LLC 2023 Form 1120-S	JF000540-000561	No
99	Johnson Foods, LLC 2023 Balance Sheet	JF000562	No
100	Johnson Foods, LLC 2023 Profit and Loss	JF000563	No
101	January 23, 2020, Distribution Agreement between Martian Sales and A1 Wholesale	DEF_MOLLER_000395-000410	Yes

#	Description	Bates Number	Pre-Admit?
102	January 23, 2020, Contract Processing Agreement between Martian Sales and Advanced Nutrition	DEF_MOLLER_000411-000418	Yes
103	October 1, 2014, Intellectual Property License Agreement between Martian Sales and Eri Wahyu Hidayat	DEF_MOLLER_000428-000432	No
104	Redacted January 31, 2025, A1 Wholesale Bank Statement	DEF_MOLLER_003652-003676	No
105	Redacted October 31, 2024, A1 Wholesale Bank Statement	DEF_MOLLER_003677-003699	No
106	Redacted November 30, 2024, A1 Wholesale Bank Statement	DEF_MOLLER_003700-003717	No
107	11/13/2020 Email	AKA_Moller0000477	No
108	Olistica Life Sciences Group – Advisory Board Call Packet	AKA_Moller0000478-0000496	No
109	11/02/2021 Email	AKA_Moller0001904	No
110	PartyNuts.com Letter	AKA_Moller0001905-0001906).	No
111	Email List	AKA_Moller0001908	No
112	PartyNuts.com Letter	AKA_Moller0001909-0001910).	No
113	01/11/2021 Email	AKA_Moller0003018	No
114	01/10/2021 AKA Invoice #101 to Jopen	AKA_Moller0003019	No
115	01/10/2021 CPSH Invoice #007 to Jopen	AKA_Moller0003020	No
116	11/01/2021 Email	AKA_Moller0003032	No
117	107/13/2021 Email	AKA_Moller0003033	No
118	07/14/2021 CPSH Invoice #016 to Jopen	AKA_Moller0003034	No

#	Description	Bates Number	Pre-Admit?
119	107/14/2021 AKA Invoice #107 to Jopen	AKA_Moller0003035	No
120	08/12/2021 Email	AKA_Moller0003153	No
121	08/14/2021 AKA Invoice #108 to Jopen	AKA_Moller0003154	No
122	08/14/2021 CPSH Invoice #017 to Jopen	AKA_Moller0003155	No
123	08/12/2021 CPSH Invoice #18 to Jopen	AKA_Moller0003156	No
124	09/17/2021 Email	AKA_Moller0003281	No
125	09/15/2021 AKA Invoice #109 to Jopen	AKA_Moller0003282	No
126	09/15/2021 AKA Invoice #110 to Jopen	AKA_Moller0003283	No
127	109/15/2021 CPSH Invoice #020 to Jopen	AKA_Moller0003284	No
128	09/15/2021 CPSH Invoice #19 to Jopen	AKA_Moller0003285	No
129	07/02/2021 Email	AKA_Moller0003316	No
130	01/27/2021 Email	AKA_Moller0003326	No
131	02/10/2021 CPSH Invoice #008 to Jopen	AKA_Moller0003327	No
132	02/10/2021 AKA Invoice #102 to Jopen	AKA_Moller0003328	No
133	02/26/2021 Email	AKA_Moller0003335	No
134	03/10/2021 AKA Invoice #103 to Jopen	AKA_Moller0003336	No
135	03/10/2021 CPSH Invoice #009 to Jopen	AKA_Moller0003337	No
136	04/27/2021 Email	AKA_Moller0003410-0003413	No
137	04/10/2021 AKA Invoice #104 to Jopen	AKA_Moller0003414	No
138	03/10/2021 AKA Invoice #103 to Jopen	AKA_Moller0003415	No
139	04/10/2021 CPSH Invoice #010 to Jopen	AKA_Moller0003416	No
140	03/10/2021 CPSH Invoice #009 to Jopen	AKA_Moller0003417	No

#	Description	Bates Number	Pre-Admit?
141	04/30/2021 Email	AKA_Moller0003418-0003421).	No
142	05/05/2021 Email	AKA_Moller0003422	No
143	05/10/2021 AKA Invoice #105 to Jopen	AKA_Moller0003423	No
144	05/04/2021 CPSH Invoice #011 to Jopen	AKA_Moller0003424	No
145	05/04/2021 CPSH Invoice #012 to Jopen	AKA_Moller0003425	No
146	05/07/2021 Email	AKA_Moller0003426	No
147	05/06/2021 CPSH Invoice #13 to Jopen	AKA_Moller0003427	No
148	06/14/2021 Email	AKA_Moller0003428	No
149	06/14/2021 AKA Invoice #106 to Jopen	AKA_Moller0003429	No
150	06/14/2021 CPSH Invoice #014 to Jopen	AKA_Moller0003430	No
151	06/14/2021 CPSH Invoice #015 to Jopen	AKA_Moller0003431	No
152	07/01/2021 Email	AKA_Moller0003433	No
153	06/14/2021 AKA Invoice #160 to Jopen	AKA_Moller0003434	No
154	06/14/2021 CPSH Invoice #014 to Jopen	AKA_Moller0003435	No
155	06/14/2021 CPSH Invoice #015 to Jopen	AKA_Moller0003436	No
156	04/08/2022 Email	AKA_Moller0004110	No
157	04/01/2022 AKA Invoice #118 to Jopen	(AKA_Moller0004111	No
158	04/01/2022 AKF Invoice #030 to Jopen	AKA_Moller0004112	No
159	AKA and AKF January 2021- April 2022 Donation Statement	(AKA_Moller0004113	No
160	04/08/2022 Email	AKA_Moller0004676	No
161	04/01/2022 AKA Invoice #118 to Jopen	AKA_Moller0004677	No
162	04/01/2022 AKA Invoice #030 to Jopen	AKA_Moller0004678	No

#	Description	Bates Number	Pre-Admit?
163	AKA and AKF January 2021- April 2022 Donation Statement	AKA_Moller0004679	No
164	12/09/2020 Email	AKA_Moller0005088	No
165	11/10/2020 CPSH Invoice #005 to Jopen.	AKA_Moller0005089	No
166	12/10/2020 CPSH Invoice #006 to Jopen	AKA_Moller0005090	No
167	12/01/2020 AKA Invoice #100 to Jopen	AKA_Moller0005091	No
168	01/10/2022 Email	AKA_Moller0008212	No
169	01/01/2022 AKA Invoice #115	AKA_Moller0008213	No
170	01/01/2022 CPSH Invoice #027 to Jopen	AKA_Moller0008214	No
171	AKA and CPSH January 2021-January 2022 Donation Statement	AKA_Moller0008215	No
172	01/10/2022 Email	AKA_Moller0008216	No
173	03/25/2021 Email	AKA_Moller0008375	No
174	03/10/2021 AKA Invoice #103 to Jopen	AKA_Moller0008376	No
175	03/10/2021 CPSH Invoice #009 to Jopen	AKA_Moller0008377	No
176	02/07/2022 Email	AKA_Moller0008691	No
177	02/01/2022 AKA Invoice #116 to Jopen	AKA_Moller0008692	No
178	02/01/2022 CPSH Invoice #028 to Jopen	AKA_Moller0008693	No
179	AKA and CPSH January 2021-February 2022 Donation Statement	AKA_Moller0008694	No
180	03/10/2022 Email	AKA_Moller0008929	No
181	03/01/2022 AKA Invoice #117 to Jopen	AKA_Moller0008930	No
182	03/01/2022 CPSH Invoice #029 to Jopen	AKA_Moller0008931	No

#	Description	Bates Number	Pre-Admit?
183	AKA and CPSH January 2021-March 2022 Donation Statement	AKA_Moller0008932	No
184	06/25/2025 Declaration of Kathy Leodler.		No
185	AKA-2021 Form 990.		No
186	CPSH-2021 Form 990.		No
187	FASB ASC 810 – Consolidation.		No
188	Defendant Martian Sales responses to Plaintiffs' First Set of Interrogatories and Request for Production of Documents.		No
189	Defendant Martian Sales responses to Plaintiffs' Second Set of Interrogatories and Request for Production of Documents.		No
190	Defendant Martian Sales responses to Plaintiffs' Third Set of Interrogatories and Request for Production of Documents.		No
191	Defendant Martian Sales supplemental responses to Plaintiffs' Third Set of Interrogatories and Request for Production of Documents.		No
192	Defendant Martian Sales responses to Plaintiffs' Fourth Set of Interrogatories and Request for Production of Documents.		No
193	Defendant JOPEN, LLC's responses to Plaintiffs' First Set of Interrogatories and Request for Production of Documents.		No
194	Defendant JOPEN, LLC's responses to Plaintiffs' Second Set of Interrogatories and Request for Production of Documents.		No
195	Defendant JOPEN, LLC's responses to Plaintiffs' Third Set of Interrogatories and Request for Production of Documents.		No

#	Description	Bates Number	Pre-Admit?
196	Defendant JOPEN, LLC's responses to Plaintiffs' Fourth Set of Interrogatories and Request for Production of Documents.		No
197	Defendant JOPEN, LLC's responses to Plaintiffs' Fifth Set of Interrogatories and Request for Production of Documents.		No
198	Defendant JOPEN, LLC's responses to Plaintiffs' Request for Admissions.		No
199	Defendant JOPEN, LLC's supplemental responses to any of Plaintiffs' request for production of documents.		No